Nasdaq · CIK 0002023016
TTRX Turn Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jun 8, 2026. Close $12.00 on Oct 9, 2026, +343% from the 52-week low and -22% from the high.
Turn Therapeutics Inc. (TTRX) has 23 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at TTRX. The newest: Zuraiz Chaudhary (See Remarks) bought $8,750 of stock on Dec 12, 2025, filed Dec 12, 2025, scored 26 (weak). The largest of the 8 shown: Arthur F Golden (director) bought $100k on Oct 23, 2025, scored 50 (moderate). 2 insiders bought within 14 days of each other around Nov 24, 2025.
TTRX closed at $12.00 on Oct 9, 2026, 343% above its 52-week low and 22% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Turn Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Zuraiz Chaudhary See Remarks buy | $8,750 2,500 shares | +25% | - | |
| 37Weak | Arthur F Golden director buy | $34k 9,868 shares | +19% | - | |
| 45Moderate | Arthur F Golden director buy | $59k 20,532 shares | +68% | - | |
| 34Weak | Zuraiz Chaudhary See Remarks buy | $7,075 2,450 shares | +32% | - | |
| 34Weak | Zuraiz Chaudhary See Remarks buy | $9,050 2,500 shares | +50% | - | |
| 26Weak | Abraham Chesed other buy | $66k 14,286 shares | +1% | - | |
| 38Weak | Zuraiz Chaudhary See Remarks buy | $25k 5,050 shares | - | - | |
| 50Moderate | Arthur F Golden director buy | $100k 20,202 shares | +202% | - |
Transactions
Every row filed, 27 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Arthur F Golden director | AGrant or award Stock option (right to buy)derivative | +89,584 | $0.00 | $0 | 89,584 | Jun 8, 2026 |
| Jun 4, 2026 | Andrew Gengos director | AGrant or award Stock option (right to buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Jun 8, 2026 |
| Jun 4, 2026 | Kent Edward Kester director | AGrant or award Stock option (right to buy)derivative | +83,334 | $0.00 | $0 | 83,334 | Jun 8, 2026 |
| Jun 4, 2026 | Martin William Dewhurst director | AGrant or award Stock option (right to buy)derivative | +71,666 | $0.00 | $0 | 71,666 | Jun 8, 2026 |
| May 28, 2026 | Bradley Evan Burnam Chief Executive Officer | GGift Common Stockindirect: By BEB Holdings, LLC | -300,000 | $0.00 | $0 | 15,416,260 | Jun 1, 2026 |
| May 28, 2026 | Bradley Evan Burnam Chief Executive Officer | GGift Common Stockindirect: See footnote | +300,000 | $0.00 | $0 | 300,000 | Jun 1, 2026 |
| May 28, 2026 | Bradley Evan Burnam Chief Executive Officer | GGift Common Stockindirect: By BEB Holdings, LLC | -300,000 | $0.00 | $0 | 15,116,260 | Jun 1, 2026 |
| May 28, 2026 | Bradley Evan Burnam Chief Executive Officer | GGift Common Stockindirect: See footnote | +300,000 | $0.00 | $0 | 300,000 | Jun 1, 2026 |
| Apr 2, 2026 | Bradley Evan Burnam Chief Executive Officer | GGift Common Stockindirect: By BEB Holdings, LLC | -300,000 | $0.00 | $0 | 15,716,260 | Apr 3, 2026 |
| Apr 2, 2026 | Arthur F Golden director | GGift Common Stock | +300,000 | $0.00 | $0 | 360,602 | Apr 3, 2026 |
| Apr 1, 2026 | Bradley Evan Burnam Chief Executive Officer | AGrant or award Employee stock option (right to buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Apr 3, 2026 |
| Apr 1, 2026 | Zuraiz Chaudhary See Remarks | AGrant or award Employee stock option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Apr 3, 2026 |
| Jan 7, 2026 | Martin William Dewhurst director | AGrant or award Common Stock | +21,882 | $0.00 | $0 | 21,882 | Feb 4, 2026 |
| Dec 12, 2025 | Zuraiz Chaudhary See Remarks | POpen-market purchase Common Stock | +2,500 | $3.50 | $8,750 | 12,500 | Dec 12, 2025 |
| Nov 24, 2025 | Arthur F Golden director | POpen-market purchase Common Stock | +9,868 | $3.44 | $34k | 60,602 | Nov 25, 2025 |
| Nov 21, 2025 | Arthur F Golden director | POpen-market purchase Common Stock | +20,532 | $2.87 | $59k | 50,734 | Nov 24, 2025 |
| Nov 20, 2025 | Zuraiz Chaudhary See Remarks | POpen-market purchase Common Stock | +1,450 | $2.61 | $3,785 | 9,000 | Nov 21, 2025 |
| Nov 21, 2025 | Zuraiz Chaudhary See Remarks | POpen-market purchase Common Stock | +1,000 | $3.29 | $3,290 | 10,000 | Nov 21, 2025 |
| Nov 17, 2025 | Zuraiz Chaudhary See Remarks | POpen-market purchase Common Stock | +2,500 | $3.62 | $9,050 | 7,550 | Nov 17, 2025 |
| Oct 23, 2025 | Abraham Chesed other | POpen-market purchase Common Stockindirect: By ANC Merchant FLP and ANC Carlson FLP | +14,286 | $4.60 | $66k | 1,447,268 | Oct 29, 2025 |
| Oct 23, 2025 | Zuraiz Chaudhary See Remarks | POpen-market purchase Common Stock | +5,050 | $4.95 | $25k | 5,050 | Oct 23, 2025 |
| Oct 23, 2025 | Arthur F Golden director | POpen-market purchase Common Stock | +20,202 | $4.95 | $100k | 30,202 | Oct 23, 2025 |
| Oct 8, 2025 | Zuraiz Chaudhary See Remarks | AGrant or award Employee stock option (right to buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Oct 10, 2025 |
| Oct 8, 2025 | Arthur F Golden director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Oct 10, 2025 |
| Oct 8, 2025 | Andrew Gengos director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Oct 10, 2025 |
| Oct 8, 2025 | Neilesh Shailesh Ghodadra Chief Medical Officer | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Oct 10, 2025 |
| Oct 8, 2025 | Kent Edward Kester director | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Oct 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bradley Evan BurnamChief Executive Officer
- Zuraiz ChaudharySee Remarks
- Abraham Chesedother
- Martin William Dewhurstdirector
- Arthur F Goldendirector
- Andrew Gengoscfo, officer, director
- Neilesh Shailesh GhodadraChief Medical Officer
- Kent Edward Kesterdirector
Questions about TTRX
Answered from the filings on this page, as of the latest one.
Are insiders buying TTRX?
No. In the last 90 days no insider at Turn Therapeutics Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TTRX on the open market?
Zuraiz Chaudhary (See Remarks) bought $8,750 of TTRX on Dec 12, 2025 and filed the Form 4 on Dec 12, 2025. InsiderTell scored 26 (weak).
How many insiders file Form 4 at Turn Therapeutics Inc.?
8 people have filed a Form 4 at Turn Therapeutics Inc., among them Bradley Evan Burnam (Chief Executive Officer), Zuraiz Chaudhary (See Remarks), Abraham Chesed (insider). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.